GlassScriptPhysician profile
Loai Marouf
NPI 1497967855
$10,514.02
in general payments reported to CMS, 2019-2025
41 companies · $1,089 in 2025
The $1,089 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,035 · 2020: $1,074 · 2021: $996 · 2022: $1,019 · 2023: $2,341 · 2024: $961 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,390.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,966.98 | 2019-2024 | Epic, Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Novartis Pharmaceuticals Corporation | $802.72 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $669.71 | 2019-2025 | Lifevest |
| Medtronic, INC. | $626.92 | 2021-2025 | Spiderfx, Linq II, Micra |
| Medtronic Vascular, INC. | $592.78 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $509.27 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $496.23 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $426.65 | 2019-2023 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor, Accolade Sr |
| Astrazeneca Pharmaceuticals LP | $397.71 | 2019-2023 | Fasenra, Farxiga, Brilinta |
| Atricure, INC. | $312.27 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Abiomed | $257.83 | 2023-2024 | Impella |
| Inspire Medical Systems, INC. | $256.39 | 2023-2024 | Inspire |
| Pfizer INC. | $241.93 | 2019-2023 | |
| Amgen INC. | $235.47 | 2019-2023 | Repatha |
| Merck Sharp & Dohme LLC | $191.25 | 2021-2023 | Verquvo |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loai Marouf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.